Novel cd19-specific γ/δ tcr-t cells in relapsed or refractory diffuse large b-cell lymphoma

HIGHLIGHTS

• who: Chenggong Li from the The first-in-human, single-center, phase , study (ClinicalTrialsgov identifier NCT04014894) was designed to evaluate the safety and efficacy of , cells in patients with u00adCD19+ malignancies, of whom eight with RR DLBCL are reported here. The inclusion criteria are provided in Supplemental Methods (Additional file, ). The study was approved by the Medical Ethics Committee of the Union Hospital affiliated to Huazhong University of Science and Technology, Wuhan, China. All patients provided written informed consent. Bridging therapy was not allowed between leukapheresis and infusion. The preconditioning regimens consisted of cyclophosphamide , mg/m, on . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.